SCHEMBL1346908

SCHEMBL1346908

CC(=O)Nc1cc(CSc2ncccc2C(=O)NNC(=O)Nc2ccccc2)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
HTT P42858 2/20 0.47
KDM4E B2RXH2 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PKM P14618 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GSK3A P49840 2/20 0.45
GSK3B P49841 2/20 0.45
AURKA O14965 1/20 0.45
ALDH1A1 P00352 3/20 0.45
CYP2C9 P11712 2/20 0.45
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.40
CRHBP P24387 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346858 0.92 KDR (0.60) KDRSMN1; SMN2LMNAMAPTHTT
SCHEMBL13604256 0.91 PKM (0.44) KDRSMN1; SMN2LMNAMAPTHTT
SCHEMBL1347067 0.89 MAPK14 (0.48) KDRSMN1; SMN2LMNAMAPTHTT
SCHEMBL1346946 0.88 PKM (0.44) KDRSMN1; SMN2LMNAMAPTHTT
SCHEMBL1344796 0.87 MAPT (0.55) KDRSMN1; SMN2LMNAMAPTHTT
SCHEMBL1347823 0.85 SMN1; SMN2 (0.51) KDRSMN1; SMN2LMNAMAPTHTT
SCHEMBL1346869 0.84 KDR (0.66) KDRSMN1; SMN2LMNAMAPTHTT
SCHEMBL1942582 0.84 KDR (0.51) KDRSMN1; SMN2LMNAMAPTHTT
SCHEMBL12133255 0.84 ALDH1A1 (0.61) KDRSMN1; SMN2HTTKDM4ETDP1
SCHEMBL1939960 0.83 KDR (0.53) KDRSMN1; SMN2LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY FLT4, VEGFA, FLT1 KDR 4/4885SMN1; SMN2 4393/4885LMNA 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.